Covered recipient · General Payments record
DAMARIS VEGA
Allopathic & Osteopathic Physicians Internal Medicine Endocrinology, Diabetes & Metabolism
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2021 · Entire year
$33,260.11
294 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2021 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $25,180.00 | 21 |
| Food and Beverage | $4,728.26 | 263 |
| Travel and Lodging | $1,731.85 | 9 |
| Consulting Fee | $1,620.00 | 1 |
By paying entity
PY2021 · entire year · sorted by reported total
Page 3 of 6; records 101–150 of 294 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
DAMARIS VEGA
NPI 1447351176 · CMS profile ID 20048
Allopathic & Osteopathic Physicians / Internal Medicine / Endocrinology, Diabetes & Metabolism
HOUSTON, TX
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 6; records 101–150 of 294 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1447351176?year=2021&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- DAMARIS VEGA, NPI 1447351176, CMS profile ID 20048. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 6; records 101–150 of 294 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1447351176?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- APA 7
- IndustryPayments. (2026). DAMARIS VEGA, NPI 1447351176, CMS profile ID 20048. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 6; records 101–150 of 294 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1447351176?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- Bluebook
- DAMARIS VEGA, NPI 1447351176, CMS profile ID 20048, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 6; records 101–150 of 294 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1447351176?year=2021&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30
294 matching records · $33,260.11 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–150 of 294.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Novo Nordisk Inc | $10.36 | 08/30/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 811342099 | CMS |
| Medtronic, Inc. | $21.48 | 08/27/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 827393467 | CMS |
| Amarin Pharma Inc. | $23.82 | 08/25/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 815039143 | CMS |
| Horizon Therapeutics plc | $17.39 | 08/25/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 797223777 | CMS |
| Novo Nordisk Inc | $11.50 | 08/25/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 810813343 | CMS |
| Novo Nordisk Inc | $10.80 | 08/25/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 811486981 | CMS |
| Amgen Inc. | $16.78 | 08/23/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 825237993 | CMS |
| AstraZeneca Pharmaceuticals LP | $23.91 | 08/21/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834352513 | CMS |
| Insulet Corporation | $5.78 | 08/20/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 839833595 | CMS |
| Clarus Therapeutics Inc. | $16.60 | 08/19/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 855028803 | CMS |
| Amarin Pharma Inc. | $18.78 | 08/17/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 815035211 | CMS |
| Novo Nordisk Inc | $9.96 | 08/16/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 811486975 | CMS |
| AbbVie Inc. | $19.22 | 08/11/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 796200761 | CMS |
| Esperion Therapeutics, Inc. | $12.27 | 08/11/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 838430003 | CMS |
| Novo Nordisk Inc | $10.60 | 08/11/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 811000947 | CMS |
| ARBOR PHARMACEUTICALS, INC. | $14.15 | 08/05/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 830948917 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $16.70 | 08/03/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 789162507 | CMS |
| MannKind Corporation | $11.84 | 08/02/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 821083935 | CMS |
| Novo Nordisk Inc | $10.81 | 08/02/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 811000939 | CMS |
| AstraZeneca Pharmaceuticals LP | $21.07 | 07/31/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834333501 | CMS |
| Novo Nordisk Inc | $129.79 | 07/30/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 811632017 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $15.55 | 07/29/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 763325986 | CMS |
| Novo Nordisk Inc | $11.23 | 07/28/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 810813339 | CMS |
| Novo Nordisk Inc | $19.04 | 07/28/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 811000931 | CMS |
| Novo Nordisk Inc | $18.69 | 07/28/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 811486971 | CMS |
| Novo Nordisk Inc | $1,755.00 | 07/28/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 811718703 | CMS |
| Novo Nordisk Inc | $16.80 | 07/27/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 811632015 | CMS |
| Novo Nordisk Inc | $11.01 | 07/26/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 810813333 | CMS |
| Insulet Corporation | $7.51 | 07/23/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 839833117 | CMS |
| Novo Nordisk Inc | $110.02 | 07/22/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 810674647 | CMS |
| Novo Nordisk Inc | $2,767.50 | 07/22/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 811000925 | CMS |
| Novo Nordisk Inc | $827.95 | 07/22/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 811632011 | CMS |
| Novo Nordisk Inc | $11.20 | 07/21/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 811000911 | CMS |
| Novo Nordisk Inc | $1,755.00 | 07/21/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 811000917 | CMS |
| Novo Nordisk Inc | $22.43 | 07/21/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 811632009 | CMS |
| Xeris Pharmaceuticals, Inc. | $23.83 | 07/20/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 837450059 | CMS |
| Novo Nordisk Inc | $10.48 | 07/19/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 811196975 | CMS |
| Insulet Corporation | $7.50 | 07/16/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 839833135 | CMS |
| Novo Nordisk Inc | $11.75 | 07/13/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 811632005 | CMS |
| Insulet Corporation | $7.75 | 07/09/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 839832973 | CMS |
| Becton, Dickinson and Company | $22.54 | 07/08/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 836114317 | CMS |
| Antares Pharma, Inc. | $14.43 | 07/07/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 827509309 | CMS |
| SANOFI-AVENTIS U.S. LLC | $6.93 | 07/07/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 843564237 | CMS |
| Amarin Pharma Inc. | $20.31 | 07/06/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 815410933 | CMS |
| AbbVie Inc. | $12.61 | 06/29/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 796200759 | CMS |
| MannKind Corporation | $19.49 | 06/28/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 821083931 | CMS |
| Novo Nordisk Inc | $10.26 | 06/28/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 810813329 | CMS |
| Insulet Corporation | $6.04 | 06/25/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 839823413 | CMS |
| VIVUS LLC | $18.64 | 06/24/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 814343435 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $15.98 | 06/22/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 763325988 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $4,267,289.52 | 294 |
| PY2024 | Principal investigator | $3,216,816.59 | 59 |
| PY2023 | Recipient | $1,216.41 | 4 |
| PY2023 | Principal investigator | $1,694,709.33 | 106 |
| PY2022 | Recipient | $152,372.75 | 15 |
| PY2022 | Principal investigator | $1,220,524.05 | 77 |
| PY2021 | Recipient | $57,978.20 | 9 |
| PY2021 | Principal investigator | $863,135.72 | 69 |
| PY2020 | Recipient | $1,234.90 | 2 |
| PY2020 | Principal investigator | $201,194.68 | 162 |
| PY2019 | Principal investigator | $320,943.37 | 107 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
294 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $5,520.00 | 12/31/2025 | Non-covered Recipient Entity JUNO RESEARCH LLC | A Phase 2/3 multicenter, double blinded, randomized, dose-conversion, active control study examining the efficacy and safety of Armour Thyroid compared to synthetic T4 for the treatment of adults with primary hypothyroidism | No dispute reported | 06/30/2026 | 1202533763 |
| Principal investigator 1 | Amgen Inc. | $8,333.00 | 12/24/2025 | Non-covered Recipient Entity JOHNSON COUNTY CLINTRIALS LLC | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (MARITIME-2) | No dispute reported | 06/30/2026 | 1246643213 |
| Principal investigator 1 | Genentech, Inc. | $34,790.00 | 12/19/2025 | Non-covered Recipient Entity JUNO RESEARCH LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211619430 |
| Principal investigator 1 | Genentech, Inc. | $16,985.00 | 12/19/2025 | Non-covered Recipient Entity JUNO RESEARCH LLC | Effect of RO7204239 in combination with tirzepatide in participants with overweight or obesity | No dispute reported | 06/30/2026 | 1211619433 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $17,200.00 | 12/19/2025 | Non-covered Recipient Entity JOHNSON COUNTY CLINTRIALS LLC | Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity | No dispute reported | 06/30/2026 | 1211619058 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $146.00 | 12/17/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220673838 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $6.96 | 12/17/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220673840 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $16.56 | 12/17/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220673842 |
| Principal investigator 1 | Genentech, Inc. | $3,333.00 | 12/11/2025 | Non-covered Recipient Entity JUNO RESEARCH LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211619425 |
| Principal investigator 1 | Genentech, Inc. | $40,436.00 | 12/04/2025 | Non-covered Recipient Entity JUNO RESEARCH LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211619422 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $12,944.00 | 12/04/2025 | Non-covered Recipient Entity JOHNSON COUNTY CLINTRIALS LLC | Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity | No dispute reported | 06/30/2026 | 1211619055 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 12/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220673654 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 12/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220673656 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 12/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220673828 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 12/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220673830 |
| Principal investigator 1 | Genentech, Inc. | $48,879.00 | 11/26/2025 | Non-covered Recipient Entity JUNO RESEARCH LLC | Effect of RO7204239 in combination with tirzepatide in participants with overweight or obesity | No dispute reported | 06/30/2026 | 1211619413 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $18,513.90 | 11/24/2025 | Non-covered Recipient Entity Johnson County ClinTrials, LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220815199 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $9,124.00 | 11/24/2025 | Non-covered Recipient Entity JUNO RESEARCH | IS354CS9 | No dispute reported | 06/30/2026 | 1246790604 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $525.00 | 11/24/2025 | Non-covered Recipient Entity JUNO RESEARCH | IS354CS9 | No dispute reported | 06/30/2026 | 1246790608 |
| Principal investigator 1 | Genentech, Inc. | $3,650.00 | 11/20/2025 | Non-covered Recipient Entity JUNO RESEARCH LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211619404 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $2,400.00 | 11/20/2025 | Non-covered Recipient Entity JOHNSON COUNTY CLINTRIALS LLC | Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity | No dispute reported | 06/30/2026 | 1211619043 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $59,379.00 | 11/20/2025 | Non-covered Recipient Entity JOHNSON COUNTY CLINTRIALS LLC | Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity | No dispute reported | 06/30/2026 | 1211619047 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $8,995.00 | 11/20/2025 | Non-covered Recipient Entity JOHNSON COUNTY CLINTRIALS LLC | Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity | No dispute reported | 06/30/2026 | 1211619051 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.96 | 11/19/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220673664 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $109.50 | 11/19/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220673666 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5.22 | 11/19/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220673668 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $12.42 | 11/19/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220673670 |
| Principal investigator 1 | Genentech, Inc. | $17,011.00 | 11/14/2025 | Non-covered Recipient Entity JUNO RESEARCH LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211619410 |
| Principal investigator 1 | Genentech, Inc. | $13,702.00 | 11/14/2025 | Non-covered Recipient Entity JUNO RESEARCH LLC | Effect of RO7204239 in combination with tirzepatide in participants with overweight or obesity | No dispute reported | 06/30/2026 | 1211619418 |
| Principal investigator 1 | Genentech, Inc. | $16,958.00 | 11/07/2025 | Non-covered Recipient Entity JUNO RESEARCH LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211619395 |
| Principal investigator 1 | ABBVIE INC. | $13,131.30 | 11/05/2025 | Non-covered Recipient Entity JUNO RESEARCH LLC | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202521975 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 11/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220673652 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 11/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220673822 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 11/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220673824 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 11/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220673826 |
| Principal investigator 1 | Genentech, Inc. | $10,945.00 | 10/29/2025 | Non-covered Recipient Entity JUNO RESEARCH LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211619369 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $2,200.00 | 10/29/2025 | Non-covered Recipient Entity JUNO RESEARCH LLC | IS354CS6 | No dispute reported | 06/30/2026 | 1246789784 |
| Principal investigator 1 | Genentech, Inc. | $28,481.00 | 10/28/2025 | Non-covered Recipient Entity JUNO RESEARCH LLC | Effect of RO7204239 in combination with tirzepatide in participants with overweight or obesity | No dispute reported | 06/30/2026 | 1211619384 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $119.88 | 10/27/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220673658 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $219.00 | 10/27/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220673660 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $10.44 | 10/27/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220673662 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $119.88 | 10/27/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220673832 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $219.00 | 10/27/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220673834 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $10.44 | 10/27/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220673836 |
| Principal investigator 1 | Genentech, Inc. | $17,381.00 | 10/23/2025 | Non-covered Recipient Entity JUNO RESEARCH LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211619392 |
| Principal investigator 1 | Genentech, Inc. | $22,083.00 | 10/16/2025 | Non-covered Recipient Entity JUNO RESEARCH LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211619365 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $83,808.00 | 10/16/2025 | Non-covered Recipient Entity JUNO RESEARCH LLC | Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity | No dispute reported | 06/30/2026 | 1211619436 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,332.00 | 10/10/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220797597 |
| Principal investigator 1 | ABBVIE INC. | $6,078.80 | 10/09/2025 | Non-covered Recipient Entity JUNO RESEARCH LLC | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202515409 |
| Principal investigator 1 | Genentech, Inc. | $40,177.00 | 10/09/2025 | Non-covered Recipient Entity JUNO RESEARCH LLC | Effect of RO7204239 in combination with tirzepatide in participants with overweight or obesity | No dispute reported | 06/30/2026 | 1211619374 |
| Principal investigator 1 | Genentech, Inc. | $13,683.00 | 10/09/2025 | Non-covered Recipient Entity JUNO RESEARCH LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211619388 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $450.00 | 10/08/2025 | Non-covered Recipient Entity JUNO RESEARCH | IS354CS9 | No dispute reported | 06/30/2026 | 1246788329 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $1,000.00 | 10/08/2025 | Non-covered Recipient Entity JUNO RESEARCH | IS354CS9 | No dispute reported | 06/30/2026 | 1246788334 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $3,000.00 | 10/08/2025 | Non-covered Recipient Entity JUNO RESEARCH | IS354CS9 | No dispute reported | 06/30/2026 | 1246788339 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $3,060.00 | 10/08/2025 | Non-covered Recipient Entity JUNO RESEARCH | IS354CS9 | No dispute reported | 06/30/2026 | 1246788344 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $15,027.50 | 10/08/2025 | Non-covered Recipient Entity JUNO RESEARCH | IS354CS9 | No dispute reported | 06/30/2026 | 1246788347 |
| Principal investigator 1 | Genentech, Inc. | $12,758.00 | 10/03/2025 | Non-covered Recipient Entity JUNO RESEARCH LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211619380 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220673650 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 10/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220673816 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220673818 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220673820 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $36.50 | 09/24/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220673648 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $36.50 | 09/24/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220673814 |
| Principal investigator 1 | Genentech, Inc. | $15,907.00 | 09/23/2025 | Non-covered Recipient Entity JUNO RESEARCH LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211619296 |
| Principal investigator 1 | Genentech, Inc. | $10,968.00 | 09/18/2025 | Non-covered Recipient Entity JUNO RESEARCH LLC | Effect of RO7204239 in combination with tirzepatide in participants with overweight or obesity | No dispute reported | 06/30/2026 | 1211619323 |
| Principal investigator 1 | Genentech, Inc. | $19,355.00 | 09/18/2025 | Non-covered Recipient Entity JUNO RESEARCH LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211619348 |
| Principal investigator 1 | Genentech, Inc. | $15,814.00 | 09/12/2025 | Non-covered Recipient Entity JUNO RESEARCH LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211619360 |
| Principal investigator 1 | Genentech, Inc. | $63,300.00 | 09/11/2025 | Non-covered Recipient Entity JUNO RESEARCH LLC | Effect of RO7204239 in combination with tirzepatide in participants with overweight or obesity | No dispute reported | 06/30/2026 | 1211619287 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $269.00 | 09/10/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220797623 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $269.00 | 09/10/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220797625 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $269.00 | 09/10/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220797627 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $269.00 | 09/10/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220797629 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $269.00 | 09/10/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220797631 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $269.00 | 09/10/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220797633 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $269.00 | 09/10/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220797635 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $269.00 | 09/10/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220797637 |
| Principal investigator 1 | Eli Lilly and Company | $111.45 | 09/09/2025 | Non-covered Recipient Entity JUNO RESEARCH LLC | A PHASE 3 STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON ONCE DAILY IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT AND OSTEOARTHRITIS OF THE KNEE: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-ARM, PLACEBO-CONTROLLED TRIAL | No dispute reported | 06/30/2026 | 1187885584 |
| Principal investigator 1 | ABBVIE INC. | $9,094.80 | 09/04/2025 | Non-covered Recipient Entity JUNO RESEARCH LLC | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202508730 |
| Principal investigator 1 | Genentech, Inc. | $21,620.00 | 09/04/2025 | Non-covered Recipient Entity JUNO RESEARCH LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211619318 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,248.00 | 09/03/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220797599 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220673632 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $30.79 | 09/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220673786 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220673788 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220673790 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 09/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220673812 |
| Principal investigator 1 | Genentech, Inc. | $33,478.00 | 08/26/2025 | Non-covered Recipient Entity JUNO RESEARCH LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211619343 |
| Principal investigator 1 | Genentech, Inc. | $5,484.00 | 08/21/2025 | Non-covered Recipient Entity JUNO RESEARCH LLC | Effect of RO7204239 in combination with tirzepatide in participants with overweight or obesity | No dispute reported | 06/30/2026 | 1211619326 |
| Principal investigator 1 | Genentech, Inc. | $5,318.00 | 08/21/2025 | Non-covered Recipient Entity JUNO RESEARCH LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211619330 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $9,630.00 | 08/20/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220797621 |
| Principal investigator 1 | Genentech, Inc. | $23,074.00 | 08/14/2025 | Non-covered Recipient Entity JUNO RESEARCH LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211619334 |
| Principal investigator 1 | Genentech, Inc. | $33,378.00 | 08/14/2025 | Non-covered Recipient Entity JUNO RESEARCH LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211619357 |
| Principal investigator 1 | Genentech, Inc. | $10,968.00 | 08/12/2025 | Non-covered Recipient Entity JUNO RESEARCH LLC | Effect of RO7204239 in combination with tirzepatide in participants with overweight or obesity | No dispute reported | 06/30/2026 | 1211619314 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $269.00 | 08/08/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220797585 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $269.00 | 08/08/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220797587 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $269.00 | 08/08/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220797589 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $269.00 | 08/08/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220797591 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $269.00 | 08/08/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220797593 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $269.00 | 08/08/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220797595 |
| Principal investigator 1 | Genentech, Inc. | $48,600.00 | 08/07/2025 | Non-covered Recipient Entity JUNO RESEARCH LLC | Effect of RO7204239 in combination with tirzepatide in participants with overweight or obesity | No dispute reported | 06/30/2026 | 1211619353 |
| Principal investigator 1 | ABBVIE INC. | $4,325.10 | 08/06/2025 | Non-covered Recipient Entity JUNO RESEARCH LLC | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202503125 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220673630 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 08/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220673810 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $8,378.00 | 08/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220797583 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $365.00 | 07/28/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220673642 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $17.40 | 07/28/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220673644 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $41.40 | 07/28/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220673646 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $4,004.10 | 07/24/2025 | Non-covered Recipient Entity JUNO RESEARCH LLC | IS354CS6 | No dispute reported | 06/30/2026 | 1246785578 |
| Principal investigator 1 | Genentech, Inc. | $30,334.00 | 07/22/2025 | Non-covered Recipient Entity JUNO RESEARCH LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211619338 |
| Principal investigator 1 | Genentech, Inc. | $64,372.00 | 07/10/2025 | Non-covered Recipient Entity JUNO RESEARCH LLC | Effect of RO7204239 in combination with tirzepatide in participants with overweight or obesity | No dispute reported | 06/30/2026 | 1211619283 |
| Principal investigator 1 | Genentech, Inc. | $29,488.00 | 07/10/2025 | Non-covered Recipient Entity JUNO RESEARCH LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211619291 |
| Principal investigator 1 | Genentech, Inc. | $31,908.00 | 07/10/2025 | Non-covered Recipient Entity JUNO RESEARCH LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211619300 |
| Principal investigator 1 | Genentech, Inc. | $32,628.00 | 07/10/2025 | Non-covered Recipient Entity JUNO RESEARCH LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211619305 |
| Principal investigator 1 | Genentech, Inc. | $19,033.00 | 07/10/2025 | Non-covered Recipient Entity JUNO RESEARCH LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211619310 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $6,376.50 | 07/09/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220797617 |
| Principal investigator 1 | ABBVIE INC. | $8,296.60 | 07/02/2025 | Non-covered Recipient Entity JUNO RESEARCH LLC | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202494979 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220673634 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220673636 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220673638 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220673640 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $61.58 | 07/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220673792 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220673794 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220673796 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220673798 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220673800 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220673802 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220673804 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220673806 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 07/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220673808 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $6,663.00 | 07/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220797579 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $12,890.70 | 06/25/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220797615 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $490.00 | 06/24/2025 | Non-covered Recipient Entity JUNO RESEARCH LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211619245 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $51,730.00 | 06/24/2025 | Non-covered Recipient Entity JUNO RESEARCH LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211619271 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $8,995.00 | 06/19/2025 | Non-covered Recipient Entity JUNO RESEARCH LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211619242 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $2,200.00 | 06/19/2025 | Non-covered Recipient Entity JUNO RESEARCH LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211619253 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $19,640.00 | 06/19/2025 | Non-covered Recipient Entity JUNO RESEARCH LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211619256 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $7,258.00 | 06/19/2025 | Non-covered Recipient Entity JUNO RESEARCH LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211619260 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $2,400.00 | 06/19/2025 | Non-covered Recipient Entity JUNO RESEARCH LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211619275 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $6,360.00 | 06/12/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220797577 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $19,877.00 | 06/12/2025 | Non-covered Recipient Entity JUNO RESEARCH LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211619249 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $300.00 | 06/04/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220797575 |
| Principal investigator 1 | ABBVIE INC. | $20,079.80 | 06/03/2025 | Non-covered Recipient Entity JUNO RESEARCH LLC | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202487667 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220673614 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220673616 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220673618 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220673620 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 06/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220673760 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220673762 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220673764 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220673766 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220673768 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220673770 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220673772 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220673774 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $233.20 | 05/27/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220673622 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $399.60 | 05/27/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220673624 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $365.00 | 05/27/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220673626 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $17.40 | 05/27/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220673628 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $233.20 | 05/27/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220673776 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $399.60 | 05/27/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220673778 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $730.00 | 05/27/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220673780 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $34.80 | 05/27/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220673782 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $41.40 | 05/27/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220673784 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $17,226.00 | 05/27/2025 | Non-covered Recipient Entity JUNO RESEARCH LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211619264 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $130.00 | 05/12/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220797581 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $130.00 | 05/12/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220797619 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $3,500.00 | 05/09/2025 | Non-covered Recipient Entity JUNO RESEARCH | a phase 3,randomised,double blind,active controlled study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on chronic kidney disease ckd progression in participants with ckd and high blood pressure | No dispute reported | 06/30/2026 | 1185550906 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $5,119.20 | 05/09/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220797611 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $13,004.00 | 05/08/2025 | Non-covered Recipient Entity JUNO RESEARCH LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211619267 |
| Principal investigator 1 | ABBVIE INC. | $15,319.20 | 05/07/2025 | Non-covered Recipient Entity JUNO RESEARCH LLC | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202483745 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $341.08 | 05/07/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220797613 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $262.74 | 05/06/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220797573 |
| Principal investigator 1 | Eli Lilly and Company | $46,480.00 | 05/05/2025 | Non-covered Recipient Entity JUNO RESEARCH LLC | A PARALLEL-GROUP TREATMENT, PHASE 2, DOUBLE-BLIND STUDY OF ONCE-WEEKLY SUBCUTANEOUS LY3457263 COMPARED TO PLACEBO IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS ON A STABLE DOSE OF TIRZEPATIDE OR SEMAGLUTIDE WHO FAILED TO ACHIEVE HBA1C GOAL | No dispute reported | 06/30/2026 | 1187883950 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $86.00 | 05/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220673604 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220673606 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220673608 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220673610 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220673612 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 05/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220673744 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220673746 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220673748 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220673750 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220673752 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220673754 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220673756 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220673758 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,463.00 | 05/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220797571 |
| Principal investigator 1 | Eli Lilly and Company | $107,745.00 | 04/28/2025 | Non-covered Recipient Entity JUNO RESEARCH LLC | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY EVALUATING THE EFFICACY AND LONG-TERM SAFETY OF TIRZEPATIDE ONCE WEEKLY COMPARED TO PLACEBO IN ADULTS WITH TYPE 1 DIABETES AND OBESITY OR OVERWEIGHT (SURPASS-T1D-2) | No dispute reported | 06/30/2026 | 1187885578 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $12,317.00 | 04/28/2025 | Non-covered Recipient Entity JUNO RESEARCH LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211619279 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $6,137.00 | 04/15/2025 | Non-covered Recipient Entity JUNO RESEARCH LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211619239 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $11,814.00 | 04/11/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220797569 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $13,339.80 | 04/11/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220797609 |
| Principal investigator 1 | ABBVIE INC. | $3,069.30 | 04/03/2025 | Non-covered Recipient Entity JUNO RESEARCH LLC | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202473641 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220673596 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220673598 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220673600 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220673602 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220673728 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220673730 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220673732 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220673734 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220673736 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220673738 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220673740 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 04/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220673742 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $7,941.60 | 03/25/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220797607 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $6,203.00 | 03/25/2025 | Non-covered Recipient Entity JUNO RESEARCH LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211619227 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $3,404.00 | 03/19/2025 | Non-covered Recipient Entity JUNO RESEARCH LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211619208 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,193.00 | 03/13/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220797567 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $1,973.00 | 03/11/2025 | Non-covered Recipient Entity JUNO RESEARCH LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211619205 |
| Principal investigator 1 | ABBVIE INC. | $7,497.10 | 03/07/2025 | Non-covered Recipient Entity JUNO RESEARCH LLC | M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202461108 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220673580 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220673582 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220673584 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220673586 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220673702 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220673704 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220673706 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220673708 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220673710 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220673712 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220673714 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 03/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220673716 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $218,228.00 | 02/28/2025 | Non-covered Recipient Entity JUNO RESEARCH | A Phase II Randomised Double blind Placebo controlled Study to Evaluate the Efficacy Safety and Tolerability of AZD5004 in Participants living with Obesity or Overweight with Comorbidity | No dispute reported | 06/30/2026 | 1185550904 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $12.42 | 02/25/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220673588 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $119.88 | 02/25/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220673590 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $328.50 | 02/25/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220673592 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $15.66 | 02/25/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220673594 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $119.88 | 02/25/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220673718 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $328.50 | 02/25/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220673720 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $15.66 | 02/25/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220673722 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $12.42 | 02/25/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220673724 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $3,463.00 | 02/25/2025 | Non-covered Recipient Entity JUNO RESEARCH LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211619223 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,326.00 | 02/20/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220797565 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $4,864.00 | 02/20/2025 | Non-covered Recipient Entity JUNO RESEARCH LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211619214 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $3,000.00 | 02/20/2025 | Non-covered Recipient Entity JUNO RESEARCH LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211619219 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $7,793.00 | 02/20/2025 | Non-covered Recipient Entity JUNO RESEARCH LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211619232 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $3,250.00 | 02/20/2025 | Non-covered Recipient Entity JUNO RESEARCH LLC | CT-388-104 OW/OB with T2D | No dispute reported | 06/30/2026 | 1211619235 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $853.20 | 02/13/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220797605 |
| Principal investigator 1 | ABBVIE INC. | $8,409.70 | 02/06/2025 | Non-covered Recipient Entity JUNO RESEARCH LLC | M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202448886 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220673572 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220673574 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220673576 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220673578 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220673686 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220673688 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220673690 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220673692 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220673694 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220673696 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220673698 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 02/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220673700 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,792.00 | 02/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220797563 |
| Principal investigator 1 | Eli Lilly and Company | $360.00 | 01/31/2025 | Non-covered Recipient Entity JUNO RESEARCH LLC | A STUDY OF ORFORGLIPRON (LY3502970) IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH DIET AND EXERCISE ALONE (ACHIEVE-1) | No dispute reported | 06/30/2026 | 1187883390 |
| Principal investigator 1 | Eli Lilly and Company | $977.28 | 01/31/2025 | Non-covered Recipient Entity JUNO RESEARCH LLC | A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH ORAL SEMAGLUTIDE IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-3) | No dispute reported | 06/30/2026 | 1187883946 |
| Principal investigator 1 | Eli Lilly and Company | $1,901.66 | 01/31/2025 | Non-covered Recipient Entity JUNO RESEARCH LLC | A PHASE 3, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY COMPARED WITH SEMAGLUTIDE ONCE WEEKLY IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN WITH OR WITHOUT SGLT2 INHIBITOR (TRANSCEND-T2D-2) | No dispute reported | 06/30/2026 | 1187885390 |
| Principal investigator 1 | Eli Lilly and Company | $1,061.92 | 01/31/2025 | Non-covered Recipient Entity JUNO RESEARCH LLC | A PHASE 3, RANDOMIZED, MULTICENTER, DOUBLE-BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES, MODERATE OR SEVERE RENAL IMPAIRMENT WITH INADEQUATE GLYCEMIC CONTROL ON BASAL INSULIN WITH OR WITHOUT METFORMIN AND/OR SGLT2 INHIBITOR | No dispute reported | 06/30/2026 | 1187885804 |
| Principal investigator 1 | Amgen Inc. | $89,025.71 | 01/30/2025 | Non-covered Recipient Entity JUNO RESEARCH LLC | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (MARITIME-2) | No dispute reported | 06/30/2026 | 1246643261 |
| Principal investigator 1 | Eli Lilly and Company | $31,622.00 | 01/28/2025 | Non-covered Recipient Entity JUNO RESEARCH LLC | A STUDY OF ORFORGLIPRON (LY3502970) IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH DIET AND EXERCISE ALONE (ACHIEVE-1) | No dispute reported | 06/30/2026 | 1187885388 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,706.40 | 01/27/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220797603 |
| Principal investigator 1 | Eli Lilly and Company | $6,020.91 | 01/27/2025 | Non-covered Recipient Entity JUNO RESEARCH LLC | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) | No dispute reported | 06/30/2026 | 1187883388 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,740.00 | 01/22/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220797561 |
| Principal investigator 1 | Eli Lilly and Company | $81.60 | 01/22/2025 | Non-covered Recipient Entity JUNO RESEARCH LLC | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE | No dispute reported | 06/30/2026 | 1187883948 |
| Principal investigator 1 | Eli Lilly and Company | $90,679.00 | 01/21/2025 | Non-covered Recipient Entity JUNO RESEARCH LLC | A STUDY OF LY3556050 IN ADULT PARTICIPANTS WITH DIABETIC PERIPHERAL NEUROPATHIC PAIN | No dispute reported | 06/30/2026 | 1187883942 |
| Principal investigator 1 | Eli Lilly and Company | $51,186.00 | 01/21/2025 | Non-covered Recipient Entity JUNO RESEARCH LLC | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) | No dispute reported | 06/30/2026 | 1187885386 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $10,560.60 | 01/17/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220797601 |
| Principal investigator 1 | Eli Lilly and Company | $1,550.46 | 01/17/2025 | Non-covered Recipient Entity JUNO RESEARCH LLC | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PROOF-OF-CONCEPT STUDY OF ONCE-WEEKLY TIRZEPATIDE PLUS MIBAVADEMAB COMPARED WITH TIRZEPATIDE ALONE IN ADULT PARTICIPANTS WITH OBESITY | No dispute reported | 06/30/2026 | 1187883392 |
| Principal investigator 1 | Amgen Inc. | $159,799.87 | 01/14/2025 | Non-covered Recipient Entity JUNO RESEARCH LLC | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | No dispute reported | 06/30/2026 | 1246643274 |
| Principal investigator 1 | Eli Lilly and Company | $2,221.63 | 01/13/2025 | Non-covered Recipient Entity JUNO RESEARCH LLC | A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR OVERWEIGHT: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (TRIUMPH-1) | No dispute reported | 06/30/2026 | 1187885808 |
| Principal investigator 1 | Eli Lilly and Company | $1,181.79 | 01/10/2025 | Non-covered Recipient Entity JUNO RESEARCH LLC | A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL ORFORGLIPRON COMPARED WITH DAPAGLIFLOZIN IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-2) | No dispute reported | 06/30/2026 | 1187883940 |
| Principal investigator 1 | Eli Lilly and Company | $6,754.24 | 01/09/2025 | Non-covered Recipient Entity JUNO RESEARCH LLC | A STUDY OF LY3556050 IN ADULT PARTICIPANTS WITH DIABETIC PERIPHERAL NEUROPATHIC PAIN | No dispute reported | 06/30/2026 | 1187886696 |
| Principal investigator 1 | Eli Lilly and Company | $2,299.03 | 01/08/2025 | Non-covered Recipient Entity JUNO RESEARCH LLC | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) | No dispute reported | 06/30/2026 | 1187883382 |
| Principal investigator 1 | Eli Lilly and Company | $390,914.00 | 01/07/2025 | Non-covered Recipient Entity JUNO RESEARCH LLC | A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR OVERWEIGHT: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (TRIUMPH-1) | No dispute reported | 06/30/2026 | 1187883384 |
| Principal investigator 1 | Eli Lilly and Company | $29,272.40 | 01/07/2025 | Non-covered Recipient Entity JUNO RESEARCH LLC | A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH ORAL SEMAGLUTIDE IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-3) | No dispute reported | 06/30/2026 | 1187883386 |
| Principal investigator 1 | Eli Lilly and Company | $262,285.00 | 01/07/2025 | Non-covered Recipient Entity JUNO RESEARCH LLC | A PHASE 3, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY COMPARED WITH SEMAGLUTIDE ONCE WEEKLY IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN WITH OR WITHOUT SGLT2 INHIBITOR (TRANSCEND-T2D-2) | No dispute reported | 06/30/2026 | 1187883944 |
| Principal investigator 1 | Eli Lilly and Company | $127,618.00 | 01/07/2025 | Non-covered Recipient Entity JUNO RESEARCH LLC | A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL ORFORGLIPRON COMPARED WITH DAPAGLIFLOZIN IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-2) | No dispute reported | 06/30/2026 | 1187884148 |
| Principal investigator 1 | Eli Lilly and Company | $53,765.00 | 01/07/2025 | Non-covered Recipient Entity JUNO RESEARCH LLC | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE | No dispute reported | 06/30/2026 | 1187884150 |
| Principal investigator 1 | Eli Lilly and Company | $94,000.00 | 01/07/2025 | Non-covered Recipient Entity JUNO RESEARCH LLC | A PHASE 3, RANDOMIZED, MULTICENTER, DOUBLE-BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES, MODERATE OR SEVERE RENAL IMPAIRMENT WITH INADEQUATE GLYCEMIC CONTROL ON BASAL INSULIN WITH OR WITHOUT METFORMIN AND/OR SGLT2 INHIBITOR | No dispute reported | 06/30/2026 | 1187884152 |
| Principal investigator 1 | Eli Lilly and Company | $174,577.16 | 01/07/2025 | Non-covered Recipient Entity JUNO RESEARCH LLC | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) | No dispute reported | 06/30/2026 | 1187885542 |
| Principal investigator 1 | Eli Lilly and Company | $104,163.00 | 01/07/2025 | Non-covered Recipient Entity JUNO RESEARCH LLC | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF INVESTIGATIONAL TIRZEPATIDE DOSES IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY | No dispute reported | 06/30/2026 | 1187885802 |
| Principal investigator 1 | Eli Lilly and Company | $659,286.00 | 01/07/2025 | Non-covered Recipient Entity JUNO RESEARCH LLC | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PROOF-OF-CONCEPT STUDY OF ONCE-WEEKLY TIRZEPATIDE PLUS MIBAVADEMAB COMPARED WITH TIRZEPATIDE ALONE IN ADULT PARTICIPANTS WITH OBESITY | No dispute reported | 06/30/2026 | 1187886692 |
| Principal investigator 1 | ABBVIE INC. | $1,946.10 | 01/02/2025 | Non-covered Recipient Entity JUNO RESEARCH LLC | M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202435283 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220673564 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220673566 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220673568 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220673570 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220673672 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220673674 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220673676 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220673678 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220673680 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220673682 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220673684 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 01/01/2025 | Non-covered Recipient Entity Juno Research North Houston | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220673726 |
| Principal investigator 1 | Eli Lilly and Company | $4,532.74 | 01/01/2025 | Non-covered Recipient Entity JUNO RESEARCH LLC | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF INVESTIGATIONAL TIRZEPATIDE DOSES IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY | No dispute reported | 06/30/2026 | 1187885806 |